See why Sapient is a preferred proteomics CRO for scientists seeking high-specificity, highly scalable protein measures with analysis that delivers deeper biological insights.
Proteins are dynamic indicators of disease and drug response, and represent the majority of targets for today’s therapeutics. Sapient leverages our mass spectrometry-based approaches to profile protein biomarkers with a breadth and depth of measure, applied to assay one to thousands of proteins at a time, in diverse sample matrices and with high specificity.
Our method is scalable from discovery screenings to singular clinical assays, and importantly captures post-translational modifications (PTMs) and proteoforms via direct peptide sequencing, allowing for more in-depth analysis of protein function and regulation.
We are a unique proteomics CRO in that we offer:
To measure up to 5,400 protein groups with exceptional reproducibility (~5% CV).
To profile as many as 3,600 protein groups including known targets of CNS disease.
To assay up to 6,000 protein groups to non-invasively probe systemic health.
To characterize 4,000 proteins groups including >500 known & emerging drug targets.
To profile 12,000+ protein groups including tumor antigens and intracellular proteins.
All methods interrogate PTMs including phosphorylation, acetylation, methylation, and ubiquitination
Supported by an advanced biocomputational framework, the Sapient team offers expert analysis of the proteomics data we generate. Central to our boinformatics pipelines is the study of proteins not only in isolation, but also as part of key biological,
signaling, and disease-oriented pathways.
As part of these efforts, we have hand annotated hundreds of key pathways and processes that are well represented in proteomics data. Through this mapping we can identify key drug targets of interest as well as biomarkers with phenotypic and disease associations.
Rely on our integrated workflows to deliver both robust protein measures and actionable insights that elucidate disease mechanisms, subtype diseases, and ultimately improve the precision and efficacy of therapies.
Explore how our discovery proteomics services can deliver unique insights to accelerate your studies.
"*" indicates required fields
